Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett has received approval from the FDA of its abbreviated new drug application for bethanechol chloride tablets in 5mg, 10mg, 25mg, and 50mg, the generic equivalent of Urecholine tablets marketed by Odyssey Pharmaceuticals.
Subscribe to our email newsletter
Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Arthur Bedrosian, president and CEO of Lannett, said: “This approval represents an important new addition to our product portfolio and is the result of the hard work and dedication of our employees. We will commence marketing our bethanechol chloride product, in the 5mg, 10mg, 25mg, and 50mg tablets, immediately.”